Cyclodextrin–Amphiphilic Copolymer Supramolecular Assemblies for the Ocular Delivery of Natamycin
- Published: 15 May 2019
- Publisher: MDPI AG
- University of Santiago de Compostela Spain
- University of Iceland Finland
- University of Iceland Iceland
Chang, H.Y., Chodosh, J.. Diagnostic and therapeutic considerations in fungal keratitis. Int. Ophthalmol. Clin.. 2011; 51: 33-42 [OpenAIRE] [PubMed] [DOI]
Mahmoudi, S., Masoomi, A., Ahmadikia, K., Tabatabaei, S.A., Soleimani, M., Rezaie, S., Ghahvechian, H., Banafsheafshan, A.. Fungal keratitis: An overview of clinical and laboratory aspects. Mycoses. 2018; 61: 916-930 [OpenAIRE] [PubMed] [DOI]
Dart, J.K., Stapleton, F., Minassian, D.. Contact lenses and other risk factors in microbial keratitis. Lancet. 1991; 338: 650-653 [PubMed] [DOI]
Green, M., Apel, A., Stapleton, F.. Risk factors and causative organisms in microbial keratitis. Cornea. 2008; 27: 22-27 [PubMed] [DOI]
Austin, A., Lietman, T., Rose-Nussbaumer, J.. Update on the management of infectious keratitis. Ophthalmology. 2017; 124: 1678-1689 [OpenAIRE] [PubMed] [DOI]
Qiu, S., Zhao, G.Q., Lin, J., Wang, X., Hu, L.T., Du, Z.D., Wang, Q., Zhu, C.C.. Natamycin in the treatment of fungal keratitis: A systematic review and Meta-analysis. Int. J. Ophthalmol.. 2015; 8: 597-602 [OpenAIRE] [PubMed] [DOI]
Patil, A., Lakhani, P., Majumdar, S.. Current perspectives on natamycin in ocular fungal infections. J. Drug Deliv. Sci. Technol.. 2017; 41: 206-212 [OpenAIRE] [DOI]
Arora, R., Gupta, D., Goyal, J., Kaur, R.. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. Clin. Exp. Ophthalmol.. 2011; 39: 434-440 [OpenAIRE] [PubMed] [DOI]
O’Day, D.M., Head, W.S., Robinson, R.D., Clanton, J.A.. Corneal penetration of topical amphotericin B and natamycin. Curr. Eye Res.. 1986; 5: 877-882 [OpenAIRE] [PubMed] [DOI]
Segura, T., Puga, A.M., Burillo, G., Llovo, J., Brackman, G., Coenye, T., Concheiro, A., Alvarez-Lorenzo, C.. Materials with fungi-bioinspired surface for efficient binding and fungi-sensitive release of antifungal agents. Biomacromolecules. 2014; 15: 1860-1870 [OpenAIRE] [PubMed] [DOI]
Cevher, E., Sensoy, D., Zloh, M., Mulazimoglu, L.. Preparation and characterisation of natamycin: Gamma-cyclodextrin inclusion complex and its evaluation in vaginal mucoadhesive formulations. J. Pharm. Sci.. 2008; 97: 4319-4335 [OpenAIRE] [PubMed] [DOI]
Saeed Nihad, A.H., Salami, M.. Study of storage conditions effect (light-heat) on natamycin content and stability in some dairy products (cheese-yoghurt). Clin. Pharmacol. Biopharm.. 2017; 6: 177 [DOI]
Bhatta, R.S., Chandasana, H., Chhonker, Y.S., Rathi, C., Kumar, D., Mitra, K., Shukla, P.K.. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Int. J. Pharm.. 2012; 432: 105-112 [OpenAIRE] [PubMed] [DOI]
Chandasana, H., Prasad, Y.D., Chhonker, Y.S., Chaitanya, T.K., Mishra, N.N., Mitra, K., Shukla, P.K., Bhatta, R.S.. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: An approach to reduce dose and dosing frequency. Int. J. Pharm.. 2014; 477: 317-325 [OpenAIRE] [PubMed] [DOI]
Patil, A., Lakhani, P., Taskar, P., Wu, K.W., Sweeney, C., Avula, B., Wang, Y.H., Khan, I.A., Majumdar, S.. Formulation development, optimization, and in vitro-in vivo characterization of natamycin-loaded PEGylated nano-lipid carriers for ocular applications. J. Pharm. Sci.. 2018; 107: 2160-2171 [OpenAIRE] [PubMed] [DOI]